Who we are
Creating a new international ophthalmic company
Nicox is a new international ophthalmic company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world.
We have already successfully completed 4 acquisitions in the ophthalmic area and we continue to actively seek and evaluate commercial and late-stage ophthalmic products as well as potential acquisitions of local ophthalmic companies in Europe’s largest markets.
Our global growth strategy is focused on outstanding international collaborations and on our proprietary nitric oxide-donating research platform.
A growing commercial portfolio
Our commercial portfolio currently includes the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. We also market a number of other ophthalmic products through our subsidiaries in Italy and in France, following the acquisitions of EuPharmed in December 2013 and of Doliage in September 2014, respectively.
We have a direct commercial presence in the five largest European markets (Germany, France, the United Kingdom, Italy and Spain), as well as partnerships with local distributors in a number of key international markets. We also intend to commercialize our future therapeutic products directly in the United States.
An innovative therapeutic pipeline
Latanoprostene bunod for IOP lowering in patients with open angle glaucoma or ocular hypertension – Complete Response Letter from the US FDA received on July 21, 2016
AC-170 for allergic conjunctivitis – New Drug Application (NDA) accepted for priority review by the U.S. FDA – PDUFA date: October 18,2016
Nicox across the globe
Nicox is headquartered in Sophia Antipolis (Nice area, France) and is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX).
Nicox has a direct commercial infrastructure in Germany (Berlin), France (Sophia Antipolis), the United Kingdom (Guildford), Italy (Bresso, Milan area) and Spain (Madrid).
Nicox also has a North American team based in Fort Worth (Texas, United States) and research capabilities in Bresso (Milan area, Italy).
Nicox employs around 124 people worldwide.